Cardiol Therapeutics
clinical stage biotech co. developing innovative therapies for inflammatory heart disease
AI Overview
With $310K in lobbying spend across 9 quarterly filings, Cardiol Therapeutics is an active lobbying client. Their lobbying covers 1 issue area. Active from 2020 to 2022.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $30K |
| 2021 | $160K |
| 2022 | $120K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Cardiol Therapeutics disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: MED
DEA's Interim Final Rule on 2018 Farm Bill as it relates to CBD, and Cardiol's Phase 2/3 FDA IND approved clinical trial for potential covid therapeutic.
Determining the control status of synthetically derived cannabidoil from the language and intent of the Implementation of the Agriculture Improvement Act of 2018.
No specific lobbying issues this quarter, determining applicable research grant opportunities
No specific lobbying issues this quarter.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.